Advertisement / Advertisement
CEO Iris Bincovich hints on Twitter that InnoCan Pharma* (NASDAQ: INNOCAN) may soon be releasing more exciting news based on Prof. Barenholz's research!
Principal in charge of InnoCan Pharma* (NYSE:PHP) research related to LPD technology, Prof. Barenholz is the author of 420 scientific publications and holds more than 55 patents. - Now he's crossed the FDA finish line with a remarkable cancer drug. The chief scientist leading research on LPT technology (CBD embedded in liposomes), Professor Chezy Barenholz, winner of the 2020 "Israeli Nobel Prize" (EMET), achieved in a research area also based on the use of liposomes, a groundbreaking breakthrough. InnoCan Pharma* (NYSE:IRIS) CEO Iris Bincovich recently informed her followers on Twitter. Another tweet from Ms. Bincovich suggests that the LPD research Professor Barenholz is conducting for Innocan also has some major news to come:
The latest published news about LPT technology! Embedded in liposomes and administered via subcutaneous injection, CBD crosses the blood/brain barrier and is detectable in the brain for 41 days:
INNOCAN REPORTS OF PRESENCE OF CBD IN MICE'S BRAINS 41 DAYS AFTER INJECTION OF CBD USING INNOCAN'S LIPOSOME PLATFORM TECHNOLOGY
With these trials, InnoCan Pharma* (NASDAQ:INNOCAN) has proven that with the LPD technology is able to cross the blood/brain barrier for CBD, which could allow CBD to exert its well-known anti-inflammatory effects directly in the brain.
In my opinion, this is relevant for diseases such as encephalitis, meningitis, multiple sclerosis, myelitis or Guillian-Barré syndrome, which originate in external infections (viruses, bacteria, fungi), but also in autoimmune reactions in the body is to be sought.
InnoCan Pharma* (WKN: A2PSPW) had recently proven several times that LPD technology can keep blood levels of CBD consistently high over a long period of time (six weeks versus 24 hours when taken orally), but that Proof that this can also be done to a similar extent in brain tissue should be given even more weight due to the possible areas of application described above.
JUST ONE OF MANY POSSIBLE USES
CBD is proven to be anti-inflammatory. Many diseases of the central nervous system are due to inflammation. As we know, the bioavailability of CBD for the human body is low because it is quickly broken down by the body. Thus, it is difficult to fully develop its healing effect. Despite this, patients - especially those with multiple sclerosis - have had great success taking CBD.
I wonder if keeping CBD levels steady in the body might even stop MS by curbing the inflammation caused by the body's autoimmune response.
Source: Meduni.com
INNOCAN PHARMA CORP.*
WKN: A2PSPW CSE: INNO
Cool thing: With an account at Smartbroker, you can trade this share from 0 euros. - Changing brokers often pays off!!
BLUECHIP-POWER
The management and the scientific advisory board of this company are of a higher caliber than you would expect from a penny stock:
Example Prof. Barenholz: This is one of the most successful and probably also most famous scientists in Israel, Prof. Chezy Barenholz, who received the "Israeli Nobel Prize", the so-called EMET Prize, for his work in 2020.
The EMET Prize, known as "Israel's Nobel Prize", which is awarded for outstanding academic and professional achievements that have had far-reaching impact and made a significant contribution to Israeli society, announced its 2020 winners in five categories: Culture and Arts, Exact Sciences, Life Sciences, Social Sciences and Humanities.
The InnoCan Pharma* (NASDAQ: PHARM) crew, which could make even many blue-chip companies green with envy, has paved the way for some biotech innovations that could make it possible to solve urgent medical problems like Covid-19 , epilepsy or Alzheimer's easily treatable and perhaps even curable.
The general public is now also becoming aware of the InnoCan Pharma (WKN: A2PSPW) stock. Alex Newman names InnoCan in the same breath as Gilead Sciences (NASDAQ GILD) and CRIPR Therapeutics (NASDAQ: CRSP):
3 biotech stocks to watch: investing.com
LPT: WITH INJECTABLE CBD AGAINST EPILEPSY:
Innocan achieves major milestone in developing its unique CBD-loaded liposome platform technology for injectable CBD.
InnoCan Pharma* (NASDAQ:INNO) announced that an animal study in mice showed prolonged release of cannabidiol ("CBD") into the blood for at least three weeks after administration. This study was conducted by the Hebrew University of Jerusalem, Israel.
The study, led by Dr. Ahuva Cern, senior researcher in the laboratory of Prof. Barenholz, was performed on over 35 mice in laboratories at the Hebrew University of Jerusalem. 21 days after injection, significant amounts of CBD were still found in the blood of mice treated with a single injection of liposomal CBD. In the second animal experiment it was even 50 days.
Cern, Bincovich, Barenholz
These results are significant when comparing oral versus smoking administration of CBD, where CBD was only found in the blood of mice for a period of up to 36 hours after administration.
Approximately 50 million people worldwide suffer from epilepsy, making it one of the most common neurological disorders worldwide. GW Pharma (NASDAQ: GWPH - $3 billion market cap) is the best-known company in the CBD pharmaceutical space and already has an approved drug (Epidyolex®) for Lennox-Gastaut Syndrome and Dravet Syndrome, two difficult-to-treat forms of childhood epilepsy. The drug must be taken twice a day.
CLX: CBD-LOADED EXOSOMES AGAINST COVID-19?
This news brought the company InnoCan Pharma* (NYSE:INNOCAN) into the focus of investors:
InnoCan Pharma Collaborates with Tel Aviv University to Develop a New Revolutionary Approach to Treat the COVID-19 Corona Virus with Exosomes-Loaded CBD
InnoCan Pharma* (WKN: A2PSPW) wants to test a treatment method against Covid-19 together with Tel Aviv University. To do this, exosomes (particles that form during the formation of stem cells) are "loaded" with CBD molecules (from the cannabis plant). Exosomes have the proven ability to find damaged cells in the body and initiate a repair process. Not only does CBD have the property of being anti-inflammatory, it can also (according to the latest research) block the "gate" through which the virus enters a cell. The innovative combination is to be introduced into the lungs attacked by Covid-19 by inhalation and, in the best case, heal them.
There is ample evidence that stem cell or exosome therapy could be the key to fighting Covid-19 disease. A landmark clinical study from Christ Hospitals in Jersey City, New Jersey, USA, has been published entitled "Bone marrow mesenchymal stem cell exosomes for the treatment of severe COVID-19" (https://pubmed.ncbi.nlm).nih.gov /32380908/).
The virus is here to stay. Vaccination will bring relief, but people will still get sick with Covid-19. An effective therapy against the so-called cytokine storm caused by the virus, which can then cause lung failure (also in other infectious lung diseases), is now the top priority of the researchers. The company recently took a huge step forward in InnoCan Pharma's promising research approach to load exosomes with CBD molecules: Innocan Pharma Successfully Completes Large Scale Production of Exosomes
With CBD AGAINST MUSCLE SONERSHIP + CBD BEAUTY PRODUCTS
InnoCan Pharma* (NYSE:InnoCan Pharma*) recently announced that 95% of testers using the Relief & Go OTC Pain Relief Spray Experience Pain Reduction (News).
Pain is the unfortunate rule in competitive sports due to the constant overstraining of joints, tendons and muscles. The patent-pending anti-pain spray tackles the problem from three sides. The combination of three active ingredients, menthol, magnesium and CBD, should make a very effective treatment possible. It should be noted that magnesium is normally only taken orally, but thanks to the patented formula it can go directly through the skin to the area of action.
InnoCan Pharma* (NYSE:InnoCan) also recently reported that its SHIR premium CBD facial serum reduced wrinkles by 90% after four weeks of treatment in a clinical study (News).
CONCLUSION:
Of course, in the short term, the main focus of investors was on the Covid-19 research. Due to its topicality, this naturally had a very broad impact. As a result, InnoCan Pharma* (NASDAQ:MMP) reached an investor audience that might have overlooked this stock at first glance. With the high-profile management directing the company's development, it should be able to put the future products and developments in perspective as well, making it highly likely that InnoCan Pharma* (NYSE:INNOCAN) could quickly develop a large following .
If you look at the price development of InnoCan over the last few months, you will see a winning share! In my opinion, this should continue in 2021.
You can find the original article HERE!
Helmut Pollinger
*Please note the following information on the conflicts of interest definitely existing at bullVestor with regard to this publication as well as our risk information and our disclaimer
Subscribe to my free newsletter
Risk Notice and Disclaimer
We expressly point out that we assume no liability for the content of external links. Every investment in securities involves risks. Political, economic or other changes can lead to significant price losses. This applies in particular to investments in (foreign) second-line stocks and in small and microcap companies. Due to the low market capitalization, investments in such securities are highly speculative and involve a high risk, up to and including the total loss of the invested capital. In addition, some of the stocks presented at bullVestor are subject to currency risks.
The background information and market assessments published by bullVestor for the German-speaking area were created in compliance with the Austrian and German capital market regulations and are therefore intended exclusively for capital market participants in the Republic of Austria and the Federal Republic of Germany. Other foreign capital market regulations were not taken into account and do not apply in any way. BullVestor's publications are for informational purposes only and expressly do not represent a financial analysis, but are promotional texts of a purely advertising nature for the companies discussed, which pay a fee for this.
By purchasing the bullVestor publications, no consulting contract comes about between the reader and the authors or the publisher. All information and analyzes do not represent an invitation, offer or recommendation to buy or sell investment instruments or for other transactions. Every investment in shares, bonds, options or other financial products is associated with risks, some of which are considerable.
The editors and authors of the bullVestor publications are not professional investment advisors. It is therefore essential that you always seek advice from a qualified specialist (e.g. your house bank or a qualified advisor you trust) when making your investment decisions. All information and data published by bullVestor comes from sources that we believe to be reliable and trustworthy at the time of writing. However, no guarantee can be given with regard to the correctness and completeness of this information and data.
The same applies to the evaluations and statements contained in bullVestor's analyzes and market assessments. These were created with due care. Any responsibility or liability for the correctness and completeness of the information contained in this publication is excluded. All statements of opinion made reflect the current assessment of the authors, which can change at any time without prior notice. There is expressly no guarantee or liability that the price or profit developments forecast in the bullVestor publications will occur.
Conflicts of interest disclosures
The publisher and responsible authors hereby declare that the following conflicts of interest exist with regard to the company discussed in this publication at the time of publication:
Imprint:
bullVestor Medien GmbHGutenhofen 44300 St. Valentin Austria Tel: +43 7435 54077-0 Company registration number: FN275279yManaging director and 100% owner: Helmut PollingerPlace of jurisdiction: St. Pöltenkontakt[at]bullvestor.at- advertisement -
Values included: CA45783P1027
